Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,181 to 1,200 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CAR-NK Cells: A Chimeric Hope or a Promising Therapy? | Cancers (Basel) | 2022 | 35954502 | PubTator, text mining | PubMed |
| Prognostic value and potential biological functions of ferroptosis-related gene signature in bladder cancer. | Oncol Lett | 2022 | 35949618 | PubTator, text mining | PubMed |
| Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. | Nat Biomed Eng | 2022 | 35941192 | PubTator, text mining | PubMed |
| Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy. | Proc Natl Acad Sci U S A | 2022 | 35939683 | PubTator, text mining | PubMed |
| CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. | Front Immunol | 2022 | 35936003 | PubTator, text mining | PubMed |
| Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation. | Front Immunol | 2022 | 35935988 | PubTator, text mining | PubMed |
| The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook. | Front Immunol | 2022 | 35935930 | PubTator, text mining | PubMed |
| Size-dependent activation of CAR-T cells. | Sci Immunol | 2022 | 35930653 | PubTator, text mining | PubMed |
| Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review. | Front Oncol | 2022 | 35928877 | PubTator, text mining | PubMed |
| The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis. | Ann Transl Med | 2022 | 35928759 | PubTator, text mining | PubMed |
| The multifaceted mechanisms of malignant glioblastoma progression and clinical implications. | Cancer Metastasis Rev | 2022 | 35920986 | PubTator, text mining | PubMed |
| Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy. | Immunother Adv | 2022 | 35919495 | PubTator, text mining | PubMed |
| Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy. | Immunother Adv | 2022 | 35919494 | PubTator, text mining | PubMed |
| Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. | Blood | 2022 | 35914226 | PubTator, text mining | PubMed |
| Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy. | J Mater Chem B | 2022 | 35912720 | PubTator, text mining | PubMed |
| Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date. | Onco Targets Ther | 2022 | 35912273 | PubTator, text mining | PubMed |
| Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. | Front Immunol | 2022 | 35911706 | PubTator, text mining | PubMed |
| Case Report: Subtotal Lymphoid and Total Marrow Irradiation as Bridge Therapy to CD19-Directed CAR T Cells in a Chemorefractory DLBCL With Leukemic Involvement. | Front Immunol | 2022 | 35911683 | PubTator, text mining | PubMed |
| Micro-hydrogel injectables that deliver effective CAR-T immunotherapy against 3D solid tumor spheroids. | Transl Oncol | 2022 | 35905640 | PubTator, text mining | PubMed |
| Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors. | Front Immunol | 2022 | 35903099 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=60